AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India disputes and clarifications
37 filed, newest first.
Sep 2026
18 Sep · Legal
Aug 2026
25 Aug · Legal
Jul 2026
30 Jul · Legal
28 Jul · Legal
Jun 2026
Jan 2026
Nov 2025
Jan 2025
Jul 2024
5 Jul · Legal
The exchange asked on 4 Jul 2024
Apr 2024
5 Apr · Legal
The exchange asked on 4 Apr 2024
Jan 2024
11 Jan · Legal
The exchange asked on 10 Jan 2024
Oct 2023
9 Oct · Legal
The exchange asked on 6 Oct 2023
Oct 2022
28 Oct · Legal
The exchange asked on 27 Oct 2022
Sep 2022
13 Sep · Legal
The exchange asked on 12 Sep 2022
Jul 2022
6 Jul · Legal
The exchange asked on 5 Jul 2022
Apr 2021
28 Apr · Legal
The exchange asked on 27 Apr 2021
Nov 2020
13 Nov · Legal
The exchange asked on 12 Nov 2020
Sep 2020
9 Sep · Legal
The exchange asked on 8 Sep 2020
Feb 2019
8 Feb · Legal
The exchange asked on 7 Feb 2019
Dec 2018
14 Dec · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 07-Dec-2018, regarding " AstraZeneca Pharma India Limited has informed the Exchange regarding 'We wish to inform that the Company and Abbott have today entered into a Distribution Agreement for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is Company's leading diabetes medicine. Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET. The Company will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo. '.". On basis of above the Company is required to clarify following: 1. Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc; 2. In case of issuance of shares to the parties, details of issue price, class of shares issued; 3. Whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length; 4. Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship; 5. Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.; 6. Shareholding, if any, in the entity with whom the agreement is executed; 7. Purpose of entering into the agreement; 8. Name(s) of parties with whom the agreement is entered; The response of the Company is awaited.
Jun 2018
12 Jun · Legal
The exchange asked on 12 Jun 2018
May 2018
22 May · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.
Jul 2017
Jun 2017
29 Jun · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 29-Jun-2017, regarding appointment of Mr. Gagan Singh Bedi as Additional Director on the Board.On basis of above you are required to clarify following -1. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.
Feb 2017
3 Feb · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to announcement dated 03-Feb-2017, regarding "AstraZeneca Pharma India Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on February 02, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Oct 2016
4 Oct · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned Embassy buys 10 acre land in Bengaluru for Rs. 255 cr .In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Mar 2015
9 Mar · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in AstraZeneca Pharma India Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has vide its letter inter-alia stated, "We have no information/announcement (including impending announcement) which in the Company's opinion may have a bearing on the price/volume behavior in the scrip."
Feb 2015
10 Feb · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "AstraZeneca to buy Actavis lung drugs". The Company has clarified that "The said news does not pertain to AstraZeneca Pharma India Limited. Rather, it comes under a separate legal entity established under the laws outside India".6 Feb · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to recent news item captioned "AstraZeneca to buy Actavis lung drugs". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
13 Oct · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "HC stays AstraZeneca s proposed delisting". The Company has clarified that "As regards Para 4 of the News Article, to the best of our understanding and as per the e-mail communication received from M/s. Res Legal, the law-firm representing the Company before Bombay High Court, the Petition was heard by the Court and disposed of finally. We are awaiting for a copy of the Order in this regard and upon receipt, we will have the same submitted to your exchange".10 Oct · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with reference to recent news item which appeared in the "Mint" dated October 10, 2014, Page No. 10, captioned "HC stays AstraZeneca s proposed delisting". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following:a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement.
Jan 2014
31 Jan · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "'AstraZeneca to close down Banglore R&D centre". The Company has clarified that "AstraZeneca R&D Centre referred to in news is not a part of the listed legal entity in India AstraZeneca Pharma India Limited. Rather, it comes under a separate legal entity which is a wholly owned subsidiary of AstraZeneca group".
Nov 2012
27 Nov · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in AstraZeneca Pharma India Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has vide its letter inter-alia stated,"We have no information/announcement(including impending announcement) which in the Company's opinion may have a bearing on the price and/or significant increase in the volume of Company's shares across exchanges."